Therapeutic potential of CB2 targeting in multiple sclerosis
- 22 January 2008
- journal article
- review article
- Published by Informa Healthcare in Emerging Therapeutic Targets
- Vol. 12 (2), 185-195
- https://doi.org/10.1517/14728222.12.2.185
Abstract
Background: Cannabinoids have been shown to exert beneficial actions in different animal models of multiple sclerosis (MS). However, the use of cannabinoids compounds in human therapy is greatly limited by their psychoactivity. Thus, new hopes in MS therapy have arisen from the evidence for a cannabinoid receptor, termed CB2, which is devoid of psychoactive effects in animal models. Objective: This review discusses the different mechanisms by which CB2 activation could induce therapeutic actions in MS. Methods: Particular focus is given to the potential effects on inflammation/autoimmunity, remyelination and neuroprotection. Conclusion: This review discusses the importance of glial cells in sustaining these effects, as well as the putative secondary effects that would limit the use of CB2 agonists in the treatment of MS. © 2008 Informa UK Ltd.Peer RevieweKeywords
This publication has 89 references indexed in Scilit:
- Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post‐natal rats through cannabinoid receptor 1 and cannabinoid receptor 2European Journal of Neuroscience, 2007
- Multiple sclerosis: Death receptor expression and oligodendrocyte apoptosis in established lesionsJournal of Neuroimmunology, 2007
- Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptorsNature Neuroscience, 2007
- Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activationMolecular and Cellular Neuroscience, 2007
- CB2 cannabinoid receptors promote mouse neural stem cell proliferationEuropean Journal of Neuroscience, 2007
- CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agentsClinical Immunology, 2006
- Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in BrainAnnals of the New York Academy of Sciences, 2006
- Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotectionProceedings of the National Academy of Sciences of the United States of America, 2006
- A role for the polysialic acid – neural cell adhesion molecule in PDGF-induced chemotaxis of oligodendrocyte precursor cellsJournal of Cell Science, 2004
- Inhibition of leukocyte adhesion by the and administration of cannabinoidsLife Sciences, 1989